PDL BioPharma

Biopharmaceutical company undergoing dissolution and asset distribution processes.
Request Access

About PDL BioPharma

PDL BioPharma is a company. It operates as a B2B, and B2C. PDL BioPharma has completed 3 acquisitions, including Eos Biotechnology, Noden Pharma DAC and TEKTURNA. PDL BioPharma offers products and services including Royalty Rights and Asset Liquidation Services.

  • Stage Public
  • Sectors
    Healthcare
    Financial Services
  • Phone
    *********
  • Website
    *********
  • Legal Name Pdl Biopharma, Inc
Operational Areas
Healthcare → Healthcare Education, Research & Associations
Financial Services → FinTech & Digital Finance
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of PDL BioPharma

PDL BioPharma offers a comprehensive portfolio of products and services, including Royalty Rights and Asset Liquidation Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Royalty rights from biopharmaceutical assets are managed and monetized as part of the dissolution process.

Assets are liquidated and claims are settled under the Plan of Dissolution to facilitate distributions.

Funding Insights of PDL BioPharma

  • Total Funding
  • Total Rounds 2
  • Last Round Post-IPO — $86.1M
  • First Round

    (18 Mar 2009)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2019 Amount Post-IPO - PDL BioPharma Valuation

investors

Mar, 2009 Amount Grant - PDL BioPharma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in PDL BioPharma

PDL BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Research Council Canada. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Scientific and technological research is conducted for Canada's benefit.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by PDL BioPharma

PDL BioPharma has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Eos Biotechnology, Noden Pharma DAC and TEKTURNA. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Producer of oil and clean-burning natural gas
2014
Information on angiotensin is provided via a dedicated webpage.
2003
Human antibody therapeutics are developed for cancer via genomics targets.
1997
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - PDL BioPharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Pdl Biopharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of PDL BioPharma

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Pdl Biopharma

Frequently Asked Questions about PDL BioPharma

What does PDL BioPharma do?

PDL BioPharma is identified as a company that has undertaken dissolution proceedings, with the Plan of Dissolution approved by stockholders in August 2020 and the Certificate of Dissolution filed in January 2021. It is noted that the companys operations are wound down through the settlement of claims and distribution of assets under Delaware law, including the use of Safe Harbor Procedures to address liabilities. Assets such as royalty rights are monetized, and interim distributions have been made, with further actions overseen by the Delaware Court of Chancery to ensure proper handling of remaining funds and obligations.

What products or services does PDL BioPharma offer?

PDL BioPharma offers Royalty Rights and Asset Liquidation Services.

How many acquisitions has PDL BioPharma made?

PDL BioPharma has made 3 acquisitions, including Eos Biotechnology, Noden Pharma DAC, and TEKTURNA.

Who are PDL BioPharma's investors?

PDL BioPharma has 1 investor. Key investors include National Research Council Canada.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available